Edgestream Partners L.P. Invests $5.87 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Edgestream Partners L.P. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 32,257 shares of the company’s stock, valued at approximately $5,872,000. Edgestream Partners L.P. owned about 0.11% of Krystal Biotech as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after purchasing an additional 7,537 shares in the last quarter. Hood River Capital Management LLC grew its stake in shares of Krystal Biotech by 5.1% in the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after buying an additional 25,507 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Krystal Biotech by 9.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock worth $43,727,000 after buying an additional 19,777 shares during the last quarter. Bank of New York Mellon Corp raised its position in Krystal Biotech by 115.7% during the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after acquiring an additional 103,928 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Krystal Biotech by 11.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company’s stock valued at $32,402,000 after acquiring an additional 18,021 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on KRYS shares. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital upped their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $202.29.

Krystal Biotech Stock Up 0.3 %

Shares of NASDAQ:KRYS opened at $197.42 on Friday. The stock has a market cap of $5.68 billion, a PE ratio of 111.54 and a beta of 0.82. Krystal Biotech, Inc. has a 12-month low of $100.78 and a 12-month high of $219.34. The business has a 50 day moving average of $180.49 and a 200-day moving average of $183.58.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.67) EPS. Equities research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).